These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25131876)

  • 21. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
    Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
    Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A case of thymic carcinoid].
    Ishikawa M; Mimoto H; Sawamura T; Hosoi Y
    Kyobu Geka; 1990 May; 43(5):413-5. PubMed ID: 2374321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence of a Thymic Carcinoid Tumour 15 Years After Resection With Multiple Myopericardial Cardiac Metastases: The Role of Multimodality Imaging.
    Promislow S; Dick A; Alzahrani A; Sekhon HS; Burwash IG; Dwivedi G
    Can J Cardiol; 2016 Dec; 32(12):1577.e15-1577.e17. PubMed ID: 27568503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients.
    Massimino K; Harrskog O; Pommier S; Pommier R
    J Surg Oncol; 2013 Jun; 107(8):842-6. PubMed ID: 23592524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Metastasized carcinoid tumor treated with interferon and octreotide].
    Szilvás A; Székely G; Szilvási I; Jakab F
    Orv Hetil; 1998 Oct; 139(41):2455-8. PubMed ID: 9805460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ectopic ACTH-syndrome due to a thymic carcinoid tumor.
    Van Schaeybroeck S; Van Imschoot S; Cochez P
    Acta Clin Belg; 2002; 57(1):23-5. PubMed ID: 12017752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carcinoid of the pancreas.
    Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
    Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Carcinoid tumors].
    Tóth M; Prónai L; Németh AM; Tulassay Z
    Orv Hetil; 2002 May; 143(19 Suppl):1087-92. PubMed ID: 12063867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
    Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
    Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
    di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
    Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic carcinoid tumor: changing patterns of care over two decades.
    Townsend A; Price T; Yeend S; Pittman K; Patterson K; Luke C
    J Clin Gastroenterol; 2010 Mar; 44(3):195-9. PubMed ID: 19609217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial.
    Loehrer PJ; Wang W; Johnson DH; Aisner SC; Ettinger DS;
    J Clin Oncol; 2004 Jan; 22(2):293-9. PubMed ID: 14722038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-standing malignant pancreatic carcinoid treated with octreotide.
    Varas-Lorenzo MJ
    Rev Esp Enferm Dig; 2010 Nov; 102(11):662-6. PubMed ID: 21142389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases.
    de Montpréville VT; Macchiarini P; Dulmet E
    J Thorac Cardiovasc Surg; 1996 Jan; 111(1):134-41. PubMed ID: 8551758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Octreotide LAR in carcinoid: how to dose?
    Yao JC; Kvols LK
    Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
    [No Abstract]   [Full Text] [Related]  

  • 37. ACTH-secreting thymic carcinoid associated with multiple endocrine neoplasia type 1.
    Yano M; Fukai I; Kobayashi Y; Mizuno K; Konishi A; Haneda H; Suzuki E; Endo K; Fujii Y
    Ann Thorac Surg; 2006 Jan; 81(1):366-8. PubMed ID: 16368411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recurrent thymic carcinoid tumor--report of a case and review of the literature].
    Souma T; Kasuya S; Irisawa T; Sakashita I; Soga J
    Nihon Kyobu Geka Gakkai Zasshi; 1992 Oct; 40(10):1938-40. PubMed ID: 1431415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carcinoid tumor and intravenous octreotide infusion during labor and delivery.
    Le BT; Bharadwaj S; Malinow AM
    Int J Obstet Anesth; 2009 Apr; 18(2):182-5. PubMed ID: 19200714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A case report of thymic carcinoid].
    Nakanishi K; Tanaka A; Sato T; Maekawa K; Watanabe N; Nakase A; Fukazawa Y; Sato H
    Kyobu Geka; 1997 Mar; 50(3):247-50. PubMed ID: 9121034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.